新強聯(300850.SZ)以1.5億元認購明陽智能非公開發行A股股票1069.9001萬股
格隆匯 11 月 20日丨新強聯(300850.SZ)公佈,近日,公司收到明陽智能簽訂的《明陽智慧能源集團股份公司與洛陽新強聯迴轉支承股份有限公司關於明陽智慧能源集團股份公司非公開發行股票之認購協議》(“股份認購協議”),公司以自有資金約1.5億元,按照每股人民幣14.02元/股認購明陽智能非公開發行A股股票1069.9001萬股。此次認購明陽智能股份於2020年11月19日在中國證券登記結算有限責任公司上海分公司辦理完畢股份登記手續。
公司此次參與認購明陽智能非公開發行的股票將有助於加強雙方協同合作,有利於拓寬公司業務結構、盤活存量金融資產、增加投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.